Biogen Inc
BIIB
Market Cap$33.49B
Close$
$281.88
22.3% upside
Current Fair Value
22.3% upsideUndervalued by 22.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.49 Billion |
|---|---|
| Enterprise Value | $38.96 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $8.0 |
| Beta | 0.0 |
| Outstanding Shares | 145,596,895 |
| Avg 30 Day Volume | 1,349,081 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 28.71 |
|---|---|
| PEG | 2024.84 |
| Price to Sales | 3.49 |
| Price to Book Ratio | 2.22 |
| Enterprise Value to Revenue | 4.03 |
| Enterprise Value to EBIT | 20.68 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...